Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2660)
05/02/2025

Indication

In combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed deat...

In combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.

Therapeutic Area

Malignant disease and immunosuppression

Status Description

Routinely available in line with national guidance

Formulation

25mg/mL concentrate for solution for infusion

Comments

Link to Advice

SMC2660

Advice Published

08/07/2024

SMC Submission Type

Full

SMC Status

Accepted